Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Diffuse Large B Cell Lymphoma
Related studies linked through entity extraction aliases.
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE4
Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Status
- RECRUITING
- Phase
- N/A
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients
- Status
- COMPLETED
- Phase
- PHASE2
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
A Study of PLX2853 in Advanced Malignancies.
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
To Decrease Fatigue With Light Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
Chidamide With R-CHOP Regimen for DLBCL Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Cyclophosphamide and Alemtuzumab In Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- N/A